

## Leading the way with integrated containment and delivery solutions



# SMARTDOSE®

GEN. I – 3.5mL

PRECISE. RELIABLE.  
READY TO GO.

### Commercially Available

- The first combination product that incorporates the SmartDose Generation (Gen.) I platform technology was recently approved by FDA and EMEA
- Installed capacity at multiple manufacturing sites
- Regulatory, Quality and Human Factors expertise to support your development

### Wearable Injector

- User loaded, subcutaneous self-administration
- Ability to deliver high volume and high viscosity drug products
- Connectivity capable

### Patient-Centric

- Easy to use, intuitive design
- Visual, tactile and audible feedback to boost user confidence
- Training solutions available for a seamless onboarding experience

### Flexible Technology

- Address a variety of delivery times through adaptable, pre-programmable technology
- Enables less painful injections through pre-programmable delivery times
- Multiple published studies\* indicate lower pain with customizable delivery rates

*"The system was easy for me to use..." (novice user)*

 **PRECISE**

 **RELIABLE**

 **READY TO GO**



### Technical Specifications

Target Tissue	Subcutaneous
Max Container Volume	Up to 3.7mL
Sterilization	Ready to Use sterile
Container Material	Daikyo Crystal Zenith® cyclic olefin polymer (COP)
Container Type	Custom cartridge with septum/cap & FluroTec® piston
Tub & Nest Format	8x8 configuration for standard filling equipment
Needle Safety System	Complies with ISO standard
Driving Mechanism	Electromechanical
System Control	Pre-programmable
Cartridge Loading	User loaded
Connectivity	Bar code capable

\*Dias, C., Abosaleem, B., Crispino, C., Gao, B. & Shaywitz, A. (2015). Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects. AAPS PharmSciTech. DOI: 10.1208/s12249-015-0288-y

Jain, M., Doughty, D., Clawson, C., Li, X., White, N., Agoram, B., & van der Merwe, R. (2017). Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates. International Journal of Clinical Pharmacology and Therapeutics, Vol. 55 (No. 7), 606-618. DOI 10.5414/CP203023

**West Pharmaceutical Services, Inc. | 530 Herman O. West Drive, Exton, PA 19341 | [www.smartdose.com](http://www.smartdose.com) |**

<b>North America</b>	<b>+1 800-345-9800</b>
<b>Europe</b>	<b>+49 2403 7960</b>
<b>Asia Pacific</b>	<b>+64 6862 3400</b>

West seeks partners for its SmartDose drug delivery platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.

West and the diamond logo, By your side for a healthier world and FluroTec® are registered trademarks or trademarks of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. SmartDose® is a registered trademark of Medimop Medical Projects Ltd., a subsidiary of West Pharmaceutical Services, Inc. Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd. Daikyo Crystal Zenith® and FluroTec® technologies are licensed from Daikyo Seiko, Ltd.